Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center Analysis | Synapse
March 3, 2026
Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center Analysis
Puntos clave
Neurotoxicity syndrome rates are significantly lower with intrathecal therapy, indicating improved patient safety.
For patients receiving intrathecal therapy, the incidence of immune effector cell-associated neurotoxicity syndrome is reduced compared to historical data.
This analysis compares outcomes using historical cohort data to assess changes in neurotoxicity risk.
The findings underline the importance of intrathecal therapy in managing immune-related side effects effectively.